Buyout Desk
Strategic

Rosemont Pharmaceuticals agrees to acquire Aytu BioPharma for $56 million

Aytu, a pharmaceutical company with the EXXUA depression drug and ADHD and pediatric products, agreed to a cash tender offer of $2.70 per share.

Target
Aytu BioPharma
Buyer
Rosemont Pharmaceuticals Holdings
Value
$56 million

Aytu BioPharma agreed on November 16, 2026 to be acquired by Rosemont Pharmaceuticals Holdings through a cash tender offer of $2.70 per share. The transaction is valued at approximately $56 million on a fully diluted basis and is expected to close by the end of calendar 2026, subject to customary closing conditions.

Aytu is a pharmaceutical company focused on medicines for complex central nervous system diseases. Its commercial portfolio includes EXXUA (gepirone) extended-release tablets for major depressive disorder, ADHD treatments and pediatric products. For the fiscal first quarter ended September 30, 2026, Aytu reported net revenue of $14.8 million, up 6.9%, and a net loss of $3.9 million.

Aytu did not hold a quarterly earnings call due to the pending transaction. The company's first-quarter results cited higher commercialization costs and merger-related legal and consulting fees.

Background

Business
Pharmaceutical company focused on complex central nervous system diseases, with the EXXUA depression drug and ADHD and pediatric products
Deal type
Strategic

Sources

Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.

Browse Healthcare deals